Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN cancer research group (E1508)

Cancer

Volumn 122, Issue 15, 2016, Pages 2371-2378

  Belani, Chandra P ^a   Dahlberg, Suzanne E ^b   Rudin, Charles M ^c   Fleisher, Martin ^c,d   Chen, Helen X ^e   Takebe, Naoko ^e   Velasco, Mario R ^f   Tester, William J ^g   Sturtz, Keren ^h   Hann, Christine L ^c   Shanks, James C ⁱ   Monga, Manish ^j   Ramalingam, Suresh S ^k   Schiller, Joan H ^l  

^a PENN STATE CANCER INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Decatur Memorial Hospital   (United States)

^g ALBERT EINSTEIN CANCER CENTER   (United States)

^h HealthEast Cancer Care ^*  (United States)

ⁱ HealthEast Cancer Care   (United States)

^j WEST VIRGINIA UNIVERSITY   (United States)

^k EMORY UNIVERSITY   (United States)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

Circulating tumor cell (CTC); Cixutumumab; Extensive disease; Small cell lung cancer; Vismodegib

Indexed keywords

ALANINE AMINOTRANSFERASE; CISPLATIN; CIXUTUMUMAB; CREATININE; ETOPOSIDE; SOMATOMEDIN C RECEPTOR; VISMODEGIB; ANILIDE; ANTI-IGF-1R ANTIBODY A12; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BODY WEIGHT LOSS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CELL COUNT; CIRCULATING TUMOR CELL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DEMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY DYSFUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; ORAL MUCOSITIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; SIDE EFFECT; SMALL CELL LUNG CANCER; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR LYSIS SYNDROME; VOMITING; AGED; CLINICAL TRIAL; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANILIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PYRIDINES; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84966687072     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30062     Document Type: Article

References (18)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol. 2006;24:4539–4544.
2. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 1999;17:1794–1801.
3. Peacock CD, Watkins DN. Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol. 2008;26:2883–2889.
4. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature. 2003;422:313–317.
5. Rubin LL, de Sauvage FJ. Targeting the hedgehog pathway in cancer. Nat Rev Drug Discov. 2006;5:1026–1033.
6. Park KS, Martelotto LG, Peifer M, et al. A crucial requirement for hedgehog signaling in small cell lung cancer. Nat Med. 2011;17: 1504–1508.
7. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev. 2002;16:2743–2748.
8. Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer. 2008;60: 166–174.
9. Marinov M, Fischer B, Arcaro A. Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol. 2007;63:172–182.
10. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20–47.
11. Ferte C, Loriot Y, Clemenson C, et al. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy. Mol Cancer Ther. 2013;12:1213–1222.
12. Normanno N, Rossi A, Morabito A, et al. Prognostic value of circulating tumor cells’ reduction in patients with extensive small-cell lung cancer. Lung Cancer. 2014;85:314–319.
13. Gualberto A, Hixon ML, Karp DD, et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer. 2011;104:68–74.
14. Giroux Leprieur E, Antoine M, Vieira T, et al. Role of the Sonic hedgehog pathway in thoracic cancers [in French]. Rev Mal Respir. 2015;32:800–808.
15. Gazdar AF. The molecular and cellular basis of human lung cancer. Anticancer Res. 1994;14:261–267.
16. Owonikoko TK, Dahlberg SE, Khan SA, et al. A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E2511). Lung Cancer. 2015;89:66–70.
17. Ott PA, Fernandez MEE, Hiret S, et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028 [abstract]. J Clin Oncol. 2015;33:7502.
18. Antonia JS, Bendell JC, Taylor MH, et al. Phase I/II study of novolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209–032 [abstract]. J Clin Oncol. 2015; 33:7503.